AS/Spondyloarthritis
4 years ago
#ABS1303 shows ASAS modification of Berlin algorithm showed optimal balance between sensitivity and specificity and represented the preferred referral strategy for patients presenting w/ undiagnosed back pain & extra-articular features. #ACR20 @RheumNow https://t.co/10VdKC3E75 https://t.co/RgC7K3V8TB
Nomenclature, Uveitis and Other Spondyloarthritis Features: Dr. Lianne Gensler
Dr. Gensler reviews her top selections for ACR 2020 today, including abstract #0881 and #0876. She also highlighted the study group on spondyloarthritis, which focused on nomenclature.
4 years ago
For all your nr-axSpA fanatics, there's a fantastic poster on certolizumab response in nr-axSpA stratified by MRI and CRP status #ACR20 @steverheum_hall https://t.co/WI1vdMItUO https://t.co/JnvAyyClDu
4 years ago
@RheumNow #acr20 abs1306 CBP highly prevalent in anterior uveitis. 53%of uveitis pts complain of CBP. 23% eventually diagnosed/meet Dx criteria for AxPsA. 87%had already had CBP w/ previous episodes of uveitis. Men more likely to be clinically diagnosed ( 33%M vs13%F). https://t.co/2y0NxJOFRp
4 years ago
So excited to check out RheumNow’s ACR Mid-Meeting Recap live right now with Dr. Jack Cush (@rheumnow), Dr. Arthur Kavanaugh, Dr. Michale Pillinger, and Dr. Bella Mehta! #ACR20
4 years ago
Ultrasound to assess synovial-entheses junction correlated with clinical findings Abs#0311
Do you use MSK US in your clinic? @RheumNow #ACR20
Treat to Target in Spondyloarthritis: Dr. Rachel Tate
Dr. Tate discusses abstracts #0879, #0893 and #1892 presented at the ACR20 annual meeting.
4 years ago
@RheumNow #acr20 abs0876 gender differences AS and nrSpA from 3 RCT IXE trials: F more likely to be older, have more nocturnal BP, peripheral pain&fatigue. M have higher CRP & +HLAB27. Ant uveitis > in M w/AS (23.8% vs. 17.9%) but > common in F w/ nr-axSpA (15.2% vs. 7.1%). https://t.co/HZa7AfWbBh
4 years ago
RheumNow’s expanded coverage of the #ACR20 Annual meeting is sponsored in part by @Novartis. All content chosen by RheumNow + its Faculty.
4 years ago
Are SpA response differences part of disease subsets or drug pharmacodynamics or both or neither? Data from COASTW & MEASURE2 @RheumNow #ACR2020 @CRASCRRheum https://t.co/GsFjZuZRvI